Spirocyclic dihydropyranopyrimidine kras inhibitors

Abstract

This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and / or sustained KRas activation (e.g., KRas activation associated with a mutant KRas protein), contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition. This disclosure also provides compositions containing the compounds provided herein, or pharmaceutically acceptable salts thereof.

Description

[0001] Spirocyclic Dihydropyranopyrimidine KRas Inhibitors CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application Serial Nos.63 / 426,950, filed November 21, 2022; 63 / 456,235, filed March 31, 2023; 63 / 515,290, filed July 24, 2023; 63 / 533,346, filed August 17, 2023; 63 / 535,006, filed August 28, 2023; 63 / 542,188, filed October 3, 2023; and 63 / 545,531, filed October 24, 2023, each of which is incorporated by reference in its entirely herein. DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY This application contains a Sequence Listing which has been submitted electronically in XML format. The Sequence Listing XML is incorporated herein by reference. The XML file, created on November 3, 2023, is named TRLN-008-007WO1_ST26_SL.xml and is 2,080 bytes in size. TECHNICAL FIELD This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas GTPase (e.g., a KRas GTPase that has a dysregulation (referred to herein as a dysregulated KRas protein)). In some embodiments, the KRas protein is a dysregulated KRas protein that has a mutation (referred to herein as a mutant KRas protein). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and / or sustained (e.g., excessive) KRas activation, such as KRas activation associated with a mutant KRas protein, contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, as well as methods of using and making the same. BACKGROUND The KRAS gene is frequently dysregulated (e.g., mutated or amplified) in various human cancers. Oncogenic mutations in KRas typically occur at hotspots in the protein such as at amino acids positions 12, 13, and 61. In some cases, a mutation can lead to maintenance of KRas activation (GTP-bound state), e.g., due to a deficiency of intrinsic GTPase activity and / or insensitivity for GTPase-activating proteins (GAPs) and consequent increased KRas signaling. Specifically, some of the most common protein mutations include those at position 12 (referred to herein as G12X) such as G12A, G12C, G12D, G12R, G12S, and G12V; position 13 (referred to herein as G13X) such as G13C, G13D, and G13V; and Q61 (referred to herein as Q61X), such as Q61E, Q61H, Q61K, Q61L, Q61P, and Q61R. KRas is widely recognized as a target for the design and development of therapies that can specifically bind and inhibit KRas signaling in cancer cells but had long been considered to be undruggable. Currently, there are few approved KRas-targeted therapies. In some embodiments, the KRas protein is a dysregulated KRas protein that has a mutation (referred to herein as a mutant KRas protein). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and / or sustained (e.g., excessive) KRas activation, such as KRas activation associated with a mutant KRas protein, contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same. SUMMARY This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein, such as a mutant KRas protein). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased KRas activation, such as KRas activation associated with a mutant KRas protein or KRas activation associated with KRas amplification, contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, as well as methods of using and making the same. Provided herein are compounds of Formula (A): or pharmaceutically acceptable salts thereof, wherein: E1is selected from the group consisting of N, CH, and CR4, wherein R4is selected from the group consisting of: CN, halo, C1-3 alkyl, C1-3 haloalkyl, and C3-6 cycloalkyl; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; R2aand R2bare independently selected from the group consisting of: H, C1-3 alkyl, C1-3haloalkyl, and C3-6cycloalkyl; or R2aand R2btaken together with the ring carbon atom to which each is attached form a C3-6 cycloalkyl ring or a 4-6 membered heterocyclyl ring; R2cand R2dare independently selected from the group consisting of: H, halo, CN, C1-3alkyl, C1-3 haloalkyl, and C3-6 cycloalkyl; or R2cand R2dtaken together with the ring carbon atom to which each is attached form a C3-6cycloalkyl ring or a 4-6 membered heterocyclyl ring; Ring B is selected from the group consisting of: , , , wherein: the * marks the ring carbon atom common to both Ring X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or a pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, and C1-6haloalkyl, or a pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (m) C(=O)N(Rf)2; (n) S(O)0-2(C1-6 alkyl); (o) S(O)0-2(C1-6 haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NRdRe, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-. Also provided herein are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Ring B is selected from the group consisting of: , , , wherein: the * marks the ring carbon atom common to both Ring X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NH2, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or a pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; Y2is a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or a pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NRdRe, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, and C1-3haloalkyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-. Also provided herein are compounds of Formula (II): Formula (II) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 1 or 2; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, and C1-6haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6haloalkoxy, -NRdRe, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-. Also provided herein are compounds of Formula (III): Formula (III) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein 30 the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; b4 is 0 or 1; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (a) halo; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NRdRe, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1- 2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. Also provided herein are compounds of Formula (IV): Formula (IV) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that at least one of X1, X2, and X3is CHRLor C(RL)2; further provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms;30and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (o) S(O)0-2(C1-6haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1- 2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. Also provided herein are compounds of Formula (V): 30 Formula (V) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that 2-3 of X1, X2, and X3are independently CHRLor C(RL)2; one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; and each additional RLis independently selected from the group consisting of: C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-. Also provided herein are compounds of Formula (VI): Formula (VI) or pharmaceutically acceptable salts thereof, wherein: R1is a 4-10 membered heterocyclyl substituted with -CN, –(C1-3 alkylene)-CN, or – (C3-6 cycloalkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; wherein each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; 30 b1 is 0, 1, or 2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, and C1-6haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (n) S(O)0-2(C1-6alkyl); (o) S(O)0-2(C1-6 haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6alkyl, C2-6alkenyl, or C2-6alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. Also provided herein are pharmaceutical compositions comprising a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Provided herein are methods for treating cancer in a subject in need thereof, the methods comprising administering to the subject a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. Also provided herein are methods for treating cancer in a subject in need thereof, the methods comprising (a) determining that the cancer has a KRas dysregulation (e.g., a KRas mutation (e.g., a KRas G12D mutation, a KRas G12R mutation, or a KRas G12V mutation)); and (b) administering to the subject a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. Provided herein are methods of treating a KRas-associated disease or disorder (e.g., a mutant KRas-associated disease or disorder (e.g., a KRas G12D-associated cancer, a KRas G12R-associated cancer, or a KRas G12V-associated cancer)) in a subject, the methods comprising administering to a subject identified or diagnosed as having a KRas-associated disease or disorder a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. This disclosure also provides methods of treating a KRas-associated disease or disorder (e.g., a mutant KRas-associated disease or disorder (e.g., a KRas G12D-associated cancer, a KRas G12R-associated cancer, or a KRas G12V-associated cancer)) in a subject, the methods comprising: determining that the disease or disorder in the subject is a KRas-associated disease or disorder (e.g., a mutant KRas-associated disease or disorder (e.g., a KRas G12D-associated disease or disorder, a KRas G12R-associated disease or disorder, or a KRas G12V-associated disease or disorder)); and administering to the subject a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. Further provided herein are methods of treating a KRas-associated cancer (e.g., a mutant KRas-associated cancer (e.g., a KRas G12D-associated cancer, a KRas G12R- associated cancer, or a KRas G12V-associated cancer)) in a subject, the methods comprising administering to a subject identified or diagnosed as having a KRas-associated cancer (e.g., a mutant KRas-associated cancer (e.g., a KRas G12D-associated cancer, a KRas G12R- associated cancer, or a KRas G12V-associated cancer)) a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. This disclosure also provides methods of treating a KRas-associated cancer (e.g., a mutant KRas-associated cancer (e.g., a KRas G12D-associated cancer, a KRas G12R- associated cancer, or a KRas G12V-associated cancer)) in a subject, the methods comprising: determining that the cancer in the subject has a KRas dysregulation (e.g., a KRas mutation (e.g., a KRas G12D mutation, a KRas G12R mutation, or a KRas G12V mutation)); and administering to the subject a therapeutically effective amount of a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as provided herein. To facilitate understanding of the disclosure set forth herein, a number of terms are provided. Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are those well-known and commonly employed in the art. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Each of the patents, applications, published applications, and other publications that are mentioned throughout the specification and the attached appendices are incorporated herein by reference in their entireties. In the case of conflict between the present disclosure and any content incorporated by reference, the present disclosure controls. The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features and advantages of the invention will be apparent from the description and drawings, and from the claims. DETAILED DESCRIPTION This disclosure provides compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein, such as a mutant KRas protein). These compounds are useful, e.g., for treating a disease, disorder, or condition associated with a KRas dysregulation (e.g., a KRas mutation or amplification) in which increased and / or sustained (e.g., excessive) KRas activation contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). These compounds can also be useful, e.g., for treating a disease, disorder, or condition in which a mutant KRas protein (e.g., a resistance mutation) confers intrinsic resistance to one or more KRas inhibitors (e.g., a KRas inhibitor selective for a KRas G12C mutant protein), or to a non-KRas-targeted therapeutic agent. See, e.g., Misale, et al., Nature 486.7404 (2012): 532-536, doi: 10.1038 / nature11156 and Awad, et al., New England Journal of Medicine 384.25 (2021): 2382-2393, doi: 10.1056 / NEJMoa2105281. This disclosure also provides compositions containing the compounds provided herein as well as methods of using and making the same. Ras family genes (e.g., KRAS, NRAS, and HRAS) were the first oncogenes identified and are some of the most commonly mutated of all discovered oncogenes. See, e.g., Hunter et al. Mol Cancer Res. 2015;13(9):1325-35, doi: 10.1158 / 1541-7786.MCR-15-0203. The Ras family are guanine nucleotide binding proteins generally found at the inner leaflet of the cell membrane. A wild type Ras protein becomes activated when bound to GTP, but it is inactive when bound to GDP. Normally, growth factors bind to extracellular receptors to induce nucleotide exchange with the help of guanine nucleotide exchange factors (GEF) (e.g., Son of sevenless homolog 1 (SOS1)). These GEFs allow GDP to dissociate from a Ras protein and GTP to bind. Ras proteins can interact with effector proteins such as cRAF when bound to GTP. Hydrolysis of GTP to form GDP can deactivate Ras proteins, and the hydrolysis can be achieved through the intrinsic GTPase activity, which may be enhanced by binding to a GTPase activating protein (GAP). There are 3 major Ras proteins in humans: KRas, HRas, and NRas. Some oncogenic KRas missense mutations can prevent or slow GTP hydrolysis and result in the accumulation of KRas in the active state. Signaling pathways associated with KRas are persistently activated in many cancers, where they participate in cellular growth and proliferation, differentiation, protein synthesis, glucose metabolism, cell survival, and inflammation. Mutant KRas proteins often have altered Raf affinity and / or altered intrinsic GTPase activity. See, for example, Table 1 reproduced from Hunter et al. Mol Cancer Res. 2015;13(9):1325-35, doi: 10.1158 / 1541-7786.MCR-15-0203. These changes and other factors can contribute to increased KRas signaling in mutant KRas proteins. Table 1

[0002] KRas inhibitors are described in, for example, International Publication Nos. WO 2023 / 154766; WO 2023 / 143623; WO 2022 / 240971; WO 2020 / 236940; WO 2022 / 115439; WO 2023 / 086383; WO 2021 / 093758; WO 2022 / 135546; WO 2021 / 139748; WO 2022 / 251576; and WO 2023 / 025116. Additional examples of KRas inhibitors are described in, for example, International Publication Nos. WO 2022 / 132200; WO 2022 / 133038; WO 2023 / 150284; WO 2022 / 261154; WO 2023 / 183585; WO 2023 / 099592; WO 2023 / 099623; WO 2023 / 099624; WO 2023 / 099608; WO 2022 / 250170; WO 2022 / 173870; WO 2022 / 236578; WO 2022 / 237649; WO 2022 / 248885; WO 2022 / 256459; WO 2022 / 258974; WO 2022 / 266015; WO 2023 / 018809; WO 2023 / 018810; WO 2023 / 018812; WO 2023 / 020518; WO 2023 / 020519; WO 2023 / 020521; WO 2023 / 020523; WO 2023 / 046135; WO 2023 / 061294; WO 2023 / 097227; WO 2023 / 114733; WO 2023 / 137223; WO 2023 / 141300; WO 2023 / 138583; WO 2023 / 159086; WO 2023 / 159087; WO 2023 / 173016; WO 2023 / 173017; WO 2023 / 179703; WO 2023 / 125627; WO 2022 / 216762; and CN 116143806. Compound Embodiments Provided herein are compounds of Formula (A): Formula (A) or pharmaceutically acceptable salts thereof, wherein: E1is selected from the group consisting of N, CH, and CR4, wherein R4is selected from the group consisting of: CN, halo, C1-3 alkyl, C1-3 haloalkyl, and C3-6 cycloalkyl; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; R2aand R2bare independently selected from the group consisting of: H, C1-3alkyl, C1-3haloalkyl, and C3-6cycloalkyl; or R2aand R2btaken together with the ring carbon atom to which each is attached form a C3-6cycloalkyl ring or a 4-6 membered heterocyclyl ring; R2cand R2dare independently selected from the group consisting of: H, halo, CN, C1-3alkyl, C1-3 haloalkyl, and C3-6 cycloalkyl; or R2cand R2dtaken together with the ring carbon atom to which each is attached form a C3-6cycloalkyl ring or a 4-6 membered heterocyclyl ring; Ring B is selected from the group consisting of: , , , wherein: the * marks the ring carbon atom common to both Ring X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or a pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, and C1-6haloalkyl, or a pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (e) -C1-6alkoxy; (f) -C1-6 haloalkoxy; (g) -NRdRe; (h) C(=O)C1-6alkyl; (i) C(=O)C1-6 haloalkyl; (j) C(=O)OH; (k) C(=O)OC1-6alkyl; (l) C(=O)OC1-6 haloalkyl; (m) C(=O)N(Rf)2; (n) S(O)0-2(C1-6alkyl); (o) S(O)0-2(C1-6haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1- 2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments, the compounds of Formula (A) are compounds of Formula (I): Formula (I) or pharmaceutically acceptable salts thereof. In some embodiments of Formula (I), R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Ring B is selected from the group consisting of: the * marks the ring carbon atom common to both Ring X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NH2, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or a pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; Y2is a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or a pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (a) halo; (b) cyano; (c) -OH; (d) oxo; (e) -C1-6alkoxy; (f) -C1-6 haloalkoxy; (g) -NRdRe; (h) C(=O)C1-6 alkyl; (i) C(=O)C1-6 haloalkyl; (j) C(=O)OH; (k) C(=O)OC1-6 alkyl; (l) C(=O)OC1-6 haloalkyl; (m)C(=O)N(Rf)2; (n) S(O)0-2(C1-6 alkyl); (o) S(O)0-2(C1-6 haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6alkyl, C2-6alkenyl, or C2-6alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, and C1-3 haloalkyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments of Formula (I), R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl substituted with -OH, -(C1-3alkylene)-OH, -CN, or – (C1-3 alkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Ring B is selected from the group consisting of: , wherein: the * marks the ring carbon atom common to both Ring X1is selected from the group consisting of a bond, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, and O, provided that no more than one of X1, X2, and X3is O; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NH2, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; Y2is a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or a pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: y y y y y each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, and C1- 3 haloalkyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-.In some embodiments of Formula (A) (e.g., Formula (I)), it is provided that when X1is a bond; and b1 is 0, then: (1) R9is OH or NRdRe(e.g., OH or NH2); or (2) Y2is a straight- chain C1-6 alkylene optionally substituted with one RY. In some embodiments of Formula (A) (e.g., Formula (I)), it is provided that one or more of (1)-(4) applies: (1) R9is OH or NRdRe; (2) b1 is 1 or 2; (3) X1is CH2; and / or (4) Y2is a straight-chain C1-6alkylene optionally substituted with one RY. In some embodiments of Formula (A) (e.g., Formula (I)), R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl substituted with -OH, -(C1-3 alkylene)-OH, -CN, or – (C1-3 alkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7; and Ring B is selected from the group consisting of: , wherein: X1is selected from the group consisting of a bond, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, and O, provided that no more than one of X1, X2, and X3is O; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, OH, NH2, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc. For avoidance of doubt, the * in each alternative of Ring B represents the * in Formula (A) (e.g., in Formula (I)). In some embodiments, the ring carbon atom labelled with * in Formula (A) (e.g., Formula (I)) has (S)-stereochemistry. In some embodiments, the ring carbon atom labelled with * in Formula (A) (e.g., Formula (I)) has (R)-stereochemistry. In some embodiments of Formula (A) (e.g., Formula (I)), Ring . In some embodiments of Formula (A) (e.g., Formula (I)), Ring . In some embodiments of Formula (A) (e.g., Formula (I)), X1is a bond. In some embodiments of Formula (A) (e.g., Formula (I)), X1is selected from the group consisting of: CH2, CHRL, and C(RL)2. For example, X1can be CH2. In some embodiments of Formula (A) (e.g., Formula (I)), X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. For example, X2and X3can both be CH2. In some embodiments of Formula (A) (e.g., Formula (I)), CH2; and X3is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (A) (e.g., Formula (I)), X2is CH2; and X3is CHRL. For example, X2can be CH2; and X3can be CHMe. In some embodiments of Formula (A) (e.g., Formula (I)), one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. For example, X2can be -O-; and X3can be CH2 or CHMe. In some embodiments of Formula (A) (e.g., Formula (I)), X1is CHRL; X2is CH2; and X3is CHRL, wherein the pair of RLtaken together with the ring atoms connecting them form a C3-6cycloalkyl ring (e.g., C4cycloalkyl ring). In some embodiments of Formula (A) (e.g., Formula (I)), Ring X1is CH2; and X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments, X2and X3are both CH2. In some embodiments, X2is CH2; 25 and X3is CHRL(e.g., CHMe). In some embodiments of Formula (A) (e.g., Formula (I)), Ring X1is CH2; one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments, X2is -O-; and X3is CH2or CHMe. In some embodiments of Formula (A) (e.g., Formula (I)), each RLis independently C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (A) (e.g., Formula (I)), Ring X1is CHRL; X2is CH2; and X3is CHRL, wherein the pair of RLtaken together with the ring atoms connecting them form a C3-6 cycloalkyl ring (e.g., C4 cycloalkyl ring). For example, Ring B can be: . In some embodiments of Formula (A) (e.g., Formula (I)), R9is para to -X3-. In some embodiments, the compounds of Formula (I) are compounds of Formula (I- a1): Formula (I-a1) or pharmaceutically acceptable salts thereof, wherein: X1is a bond or CH2; X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2 (e.g., 0 or 1). In some embodiments, the compounds of Formula (I) are compounds of Formula (I- b1): or pharmaceutically acceptable salts thereof, wherein: X1is a bond or CH2; X2and X3are independently selected from the group consisting of: -O-, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2. In some embodiments, the compounds of Formula (I) are compounds of Formula (I- b1): Formula (I-c1) or pharmaceutically acceptable salts thereof, wherein: X1is a bond or CH2; X2and X3are independently selected from the group consisting of: -O-, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X1is a bond. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X1is CH2. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X2and X3are both CH2. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X2is CH2; and X3is selected from the group consisting of: CHRLand C(RL)2. For example, X2can be CH2; and X3can be CHMe. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X1is CH2; and X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments, X2and X3are both CH2. In some embodiments, X2is CH2; and X3is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (I-a1), (I-b1), or (I-c1), X1is CH2; one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments, X2is -O-; and X3is CH2 or CHMe. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is selected from the group consisting of -OH, -NH2, and halo. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is selected from the group consisting of -OH and -NRdRe. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is selected from the group consisting of -OH and -NH2. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is -OH. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is -NH2. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is halo (e.g., -Br). In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R9is H. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 0 or 1. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 1 or 2. For example, b1 can be 1. For example, b1 can be 2. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 1 or 2; and each R10is independently selected from the group consisting of: - Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 1; and R10is -CN. In some embodiments, b1 is 1; R10is ortho to R9; and R10is -CN. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 1 or 2; and each R10is independently -Cl or -F. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 1 or 2; 1-2 occurrence(s) of R10is ortho to R9; and each R10is independently -Cl or -F. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), b1 is 0. In some embodiments of Formula (A) (e.g., Formula (I)), Ring B is selected from the wherein: X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (A) (e.g., Formula (I)), Ring B is selected from the group consisting of: , wherein: X2is -O- or -CH2- ; X3is -CH2- or -CHRL-, wherein RLis C1-3alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (A) (e.g., Formula (I)), Ring B is selected from the In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl substituted with -OH, -(C1-3alkylene)-OH, -(C3-6cycloalkylene)-OH, -CN, –(C1-3alkylene)-CN, or –(C3-6cycloalkylene)-CN, on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is 4-10 membered heterocyclyl optionally substituted with 1-4 R7. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is a 4-10 membered heterocyclyl substituted with -OH, -(C1-3 alkylene)-OH, - CN, or –(C1-3 alkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is a 4-10 (e.g., 6, 7, or 8) membered heterocyclyl substituted with -OH or - CH2CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7, and wherein the heterocyclyl contains one ring nitrogen atom and 0-2 additional ring heteroatoms each independently selected from the group consisting of: O and S(O)0-2. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) further optionally substituted with 1-2 R7at one or more ring carbon atoms. For example, R1can In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is a 7-10 (e.g., 7) membered heterocyclyl optionally substituted with 1-4 R7. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is a 7-10 (e.g., 7) membered heterocyclyl having one ring nitrogen atom, one ring oxygen atom, and no additional ring heteroatoms, wherein the 7-10 membered heterocyclyl is optionally substituted with 1-4 R7. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) optionally substituted with 1-4 R7at one or more ring carbon atoms. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3 alkyl optionally substituted with 1-3 Rc, wherein: each Rcis independently selected from the group consisting of: -F, -OH, and -CN. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R1is an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms. For example, R1can In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) , wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7. In some embodiments, A2is CH. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) example, R1can . In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1)) R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), Y2is -CH2-. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R3is a 4-10 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), or (I-c1))), R3is a bicyclic 7-10 membered heterocyclyl optionally substituted with 1-6 Ra. In some embodiments of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-b1), In some embodiments, the compounds of Formula (I) are compounds of Formula (I- a2) or (I-b2): Formula (I-a2) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: ; X1is a bond or CH2; X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2 (e.g., 0 or 1). In some embodiments, the compounds of Formula (I) are compounds of Formula (I- a3) or (I-b3): or pharmaceutically acceptable salts thereof, wherein: R1is a 7-10 membered heterocyclyl having one ring nitrogen atom, one ring oxygen atom, and no additional ring heteroatoms, wherein the 7-10 membered heterocyclyl is optionally substituted with 1-4 R7; X1is CH2; X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2. In some embodiments, the compounds of Formula (I) are compounds of Formula (I- a4) or (I-b4): Formula (I-b4) or a pharmaceutically acceptable salt thereof, wherein: b3 is 0, 1, 2, or 3; X1is CH2; X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2. In some embodiments of Formula (I-a4) or (I-b4), b3 is 0. In some embodiments of Formula (I-a4) or (I-b4), b3 is 1 or 2; and each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc, wherein each Rcis independently selected from the group consisting25of: -F, -OH, and -CN. In some embodiments, the compounds of Formula (I) are compounds of Formula (I- a5) or (I-b5): Formula (I-b5) or a pharmaceutically acceptable salt thereof, wherein: R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2; and b1 is 0, 1, or 2. In some embodiments of Formula (I-a5) or (I-b5), R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), X2and X3are both CH2. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), X2is CH2; and X3is CHRL. For example, X2can be CH2; and X3can be CH(Me). In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), X2is -O-; and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. For example, X2can be -O-; and X3can be CH2or CH(Me). In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), R9is -NH2. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), R9is -OH. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), b1 is 1. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I- b4), (I-a5), or (I-b5), b1 is 2. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), b1 is 0. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), b1 is 1 or 2; and each R10is independently selected from the group consisting of: - Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (I-a2), (I-a3), (I-a4), or (I-a5), the30 moiety is selected from the group consisting of: , , wherein: X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (I-a2), (I-a3), (I-a4), or (I-a5), the X3is -CH2- or -CHRL-, wherein RLis C1-3alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (I-a2), (I-a3), (I-a4), or (I-a5), the In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), the ring carbon atom labelled with * in Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5) has (S)-stereochemistry. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5), the ring carbon atom labelled with * in Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), or (I-b5) has (R)-stereochemistry. In some embodiments of Formula (I-a2), (I-b2), (I-a3), (I-b3), (I-a4), (I-b4), (I-a5), In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are selected from the group consisting of compounds depicted in Table C1, or pharmaceutically acceptable salts thereof. Table C1 142a 143 143a 143b 144

[0003] Note 1: In some compounds as filed in U.S. Provisional Application Serial No. 63 / 515,290 (e.g., Compounds Nos. 143a, 143b, 149b, and 149c), a stereogenic center was previously denoted with a “*,” this stereogenic center was resolved, but its absolute configuration was not assigned. Herein, the compound structures have been redrawn with enhanced stereochemical notation. See Note 2. Note 2: In certain compounds of Table C1, one or more stereogenic centers are denoted with the “V3000 enhanced stereochemical notation” (see: support.collaborativedrug.com / hc / en- us / articles / 360020872171-Advanced-Stereochemistry-Registration-Atropisomers-Mixtures- Unknowns-and-Non-Tetrahedral-Chirality, accessed on December 23, 2022 and Accelrys Chemical Representation Guide, Accelrys Software Inc., 2014, each of which is incorporated by reference herein in its entirety). Using this stereochemical notation, certain stereogenic centers are denoted with “abs”, “&x”, or “orx”, wherein x is an integer (e.g., 1 or 2). For avoidance of doubt, the stereochemical notations in Table C1 have the following meaning: When a structure does not contain any wedged or hashed bonds (i.e., each stereogenic center is undefined), then each stereogenic center can independently adopt a (R) or (S) stereochemical configuration. For avoidance of doubt, such structures also encompass mixtures of stereoisomers. For example, p , , or a mixture . When a structure contains a stereogenic center or a plurality of stereogenic centers that is depicted with wedges and hashes (i.e., one or more stereogenic center is defined), the following notations are used: (1) When a defined stereogenic center is denoted with “abs” or when the defined stereogenic center is not denoted with an enhanced stereochemical notation (e.g., “abs”, “&x”, or “orx”), the defined stereogenic center has the absolute configuration as depicted by the structural formula. For example, both of the structures and refer to (S)-(1-methylpyrrolidin-2-yl)methanol. (2) When a defined stereogenic center is denoted with “orx” in a structural formula, the defined stereogenic center has been resolved but the configuration at the defined stereogenic center has not been determined. For example, the structure refers to one stereoisomer selected from the group consisting of (S)-(1-methylpyrrolidin-2-yl)methanol and (R)-(1-methylpyrrolidin-2-yl)methanol. (3) When a stereogenic center is undefined (i.e., no wedged or hashed bonds attached to the undefined stereogenic center) in a structural formula having at least one defined stereogenic center (i.e., having a wedged and / or hashed bond attached to the at least one defined stereogenic center), a mixture of stereoisomers differing at the undefined stereogenic center is represented. For example, the structure represents a mixture of (4) When two or more defined stereogenic centers are denoted with “orx” in a structural formula, each of these defined stereogenic centers has been resolved but the configurations at the defined stereogenic centers have not been determined. Specifically: a. For any pair of defined stereogenic centers denoted with “orx” in a structural formula, when the numerical parts in the notation are different (e.g., two defined stereogenic centers denoted with “or1” and “or2” respectively), each defined stereogenic center should be independently interpreted according to “(2)” supra. For example, the structure refers to one stereoisomer selected , b. For any pair of defined stereogenic centers denoted with “orx” in a structural formula, when the numerical part in the notation is identical (e.g., two defined stereogenic centers are each denoted with “or1”), the structural formula refers to one stereoisomer having the relative stereochemistry at these stereogenic centers as depicted in the structural formula, but the absolute configurations of these stereogenic centers have not been determined. For example, the structure . another example, the structure refers to one of the “anti” stereoisomers: . (5) When two or more defined stereogenic centers are denoted with “&x” in a structural formula, the structural formula refers to a mixture of stereoisomers that differ in the configuration at the defined stereogenic centers. Specifically: a. For any pair of defined stereogenic centers denoted with “&x” in a structural formula, when the numerical parts in the notation are different (e.g., two defined stereogenic centers denoted with “&1” and “&2” respectively), the structural formula refers to a mixture of stereoisomers at these two defined stereogenic centers, wherein the configuration at each of the defined stereogenic centers can vary independently of one another. For example, the structure refers to a mixture of four stereoisomers: , b. For any pair of defined stereogenic centers denoted with “&x” in a structural formula, when the numerical part in the notation is identical (e.g., two defined stereogenic centers are each denoted with “&1”), the structural formula refers to a mixture of stereoisomers at these two defined stereogenic centers, wherein the relative configurations are as depicted in the structural formula. For example, the structure refers to a mixture of “syn” stereoisomers: . another example, the . In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are selected from the group consisting of compounds depicted in Table C1s of U.S. Provisional Application Serial Nos. 63 / 426,950, filed November 21, 2022; 63 / 456,235, filed March 31, 2023; 63 / 515,290, filed July 24, 2023; 63 / 533,346, filed August 17, 2023; 63 / 535,006, filed August 28, 2023; 63 / 542,188, filed October 3, 2023; and 63 / 545,531, filed October 24, 2023, or pharmaceutically acceptable salts thereof, each of the Table C1s is incorporated by reference in its entirety herein. In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are compounds of Formula (II): Formula (II) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 1 or 2; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (k) C(=O)OC1-6alkyl; (l) C(=O)OC1-6 haloalkyl; (m) C(=O)N(Rf)2; (n) S(O)0-2(C1-6alkyl); (o) S(O)0-2(C1-6 haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6alkyl, C2-6alkenyl, or C2-6alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments, the compounds of Formula (II) are compounds of Formula (II- Formula (II-a) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (II) are compounds of Formula (II- b): Formula (II-b) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are compounds of Formula (III): Formula (III) or pharmaceutically acceptable salts thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; b4 is 0 or 1; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments of Formula (III), R9is selected from the group consisting of: NRdRe, -OH, and halo. In some embodiments of Formula (III), R9is NRdRe. In some embodiments of Formula (III), R9is -NH2; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X1is CH2 or CHRL. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X1is CH2; and X2and X3are both CH2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), at least one of X1, X2, and X3is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), one of X1, X2, and X3(e.g., X3) is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X1is CH2; and X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2, provided that 1-2 (e.g., one) of X2and X3is independently CHRLor C(RL)2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X1is CH2; X2is CH2; and X3is CHRL. In some embodiments, each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), X2is -O-; and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments, each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)) or Formula (III), each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F. In some embodiments of Formula (II), the moiety is selected from b4 is 0 or 1; X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. . In some embodiments of Formula (III), the moiety is , wherein: b4 is 0 or 1; X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3 alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. , In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are compounds of Formula (IV): Formula (IV) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that at least one of X1, X2, and X3is CHRLor C(RL)2; further provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments of Formula (IV), R9is selected from the group consisting of: OH, NRdRe, and halo. For example, R9can be NRdRe. In some embodiments, the compounds of Formula (IV) are compounds of Formula (IV- Formula (IV-a) or pharmaceutically acceptable salts thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (IV) are compounds of Formula (IV- b): Formula (IV-b) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (IV) (e.g., Formula (IV-a) or (IV-b)), X1is CH2. In some embodiments of Formula (IV) (e.g., Formula (IV-a) or (IV-b)), X2is CH2; and X3is CHRL. In some embodiments of Formula (IV) (e.g., Formula (IV-a) or (IV-b)), X2is -O-; and X3is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (IV) (e.g., Formula (IV-a) or (IV-b)), each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F. In some embodiments, the compounds of Formula (IV) are compounds of Formula (IV- c): Formula (IV-c) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (A) (e.g., Formula (I)) are compounds of Formula (V): Formula (V) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that 2-3 of X1, X2, and X3are independently CHRLor C(RL)2; one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; and each additional RLis independently selected from the group consisting of: C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii) , wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments, the compounds of Formula (V) are compounds of Formula (V- Formula (V-a) or pharmaceutically acceptable salts thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (V) are compounds of Formula (V- b): Formula (V-b) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (V) (e.g., Formula (V-a) or (V-b)), X2is -O- or - CH2- (e.g., -CH2-). In some embodiments of Formula (V) (e.g., Formula (V-a) or (V-b)), X1is CHRL; and X3is CHRL, wherein the pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4cycloalkyl ring. In some embodiments of Formula (V) (e.g., Formula (V-a) or (V-b)), X1is CHRL; and X3is C(RL)2, wherein the pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4cycloalkyl ring, and the remaining RLis C1-2alkyl optionally substituted with 1-3 F. In some embodiments, the compounds of Formula (V) are compounds of Formula (V- c) or Formula (V-d): Formula (V-c) Formula (V-d) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; the pair of RL1taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring, and RL2is C1-2alkyl optionally substituted with 1-3 F. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), R1is , wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom. In some embodiments, R7is C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh. In some embodiments, R7is Rb1, wherein the Rb1is 5-6 membered heteroaryl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-2 Rg. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), wherein R7aand R7bare independently selected R7. In some embodiments, R7ais selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1; and R7bis -halo, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments, R7ais selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3 alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom. In some embodiments, R7ais Rb1, wherein the Rb1is 5-6 membered heteroaryl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-2 Rg. In some embodiments, R7bis halo (e.g., -Cl). In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), R1is a 7-10 (e.g., 7) membered heterocyclyl having one ring nitrogen atom, one ring oxygen atom, and no additional ring heteroatoms, wherein the 7-10 membered heterocyclyl is optionally substituted with 1-4 R7. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), optionally substituted with 1-4 R7at one or more ring carbon atoms. For example, R1can . In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3 alkyl optionally substituted with 1-3 Rc, wherein: each Rcis independently selected from the group consisting of: -F, -OH, and -CN. In some embodiments of Formula (II) (e.g., Formula (II-a) or (II-b)), Formula (III), Formula (IV) (e.g., Formula (IV-a), (IV-b), or (IV-c)), or Formula (V) (e.g., Formula (V-a), (V-b), (V-c), or (V-d)), optionally substituted with 1-4 R7at one or more ring carbon atoms, wherein each R7is independently selected from the group consisting of: -OH; - CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc, wherein: each Rcis independently selected from the group consisting of: -F, -OH, and -CN. In some embodiments, the compounds of Formula (II) are compounds of Formula (II- a1) or (II-b1): Formula (II-a1) Formula (II-b1) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2. In some embodiments, the compounds of Formula (III) are compounds of compound of Formula (III-1): Formula (III-1) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2;. In some embodiments of Formula (III-1), R9is NRdRe(e.g., -NH2). In some embodiments, the compounds of Formula (IV) are compounds of Formula (IV- a1) or (IV-b1): Formula (IV-b1) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; one of X2and X3is independently selected from the group consisting of: CHRLand C(RL)2; and the other of X2and X3is CH2or O. In some embodiments of Formula (IV-a1) or (IV-b1), X2is CH2; and X3is CHRL. In some embodiments of Formula (IV-a1) or (IV-b1), R9is NRdRe(e.g., -NH2). In some embodiments, the compounds of Formula (V) are compounds of Formula (V- a1) or (V-b1): Formula (V-b1) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X2is -O- or -CH2-; X1is CHRL; and X3is CHRLor C(RL)2, wherein: one pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring; and the remaining RLif present is C1-2 alkyl optionally substituted with 1-3 F. In some embodiments of Formula (II-a1), (II-b1), (III-1), (IV-a1), (IV-b1), (V-a1), or (V-b1), b3 is 0. In some embodiments of Formula (II-a1), (II-b1), (III-1), (IV-a1), (IV-b1), (V-a1), or (V-b1), b3 is 1 or 2; and each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3 alkyl optionally substituted with 1-3 Rc, wherein each Rcis independently selected from the group consisting of: -F, -OH, and -CN. In some embodiments, the compounds of Formula (II) are compounds of Formula (II- a2) or (II-b2): Formula (II-b2) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2. In some embodiments, the compounds of Formula (III) are compounds of Formula (III-2): Formula (III-2) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2. In some embodiments of Formula (III-2) R9is NRdRe(e.g., -NH2). In some embodiments, the compounds of Formula (IV) are compounds of compound of Formula (IV-a2) or (IV-b2): Formula (IV-a2) Formula (IV-b2) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; one of X2and X3is independently selected from the group consisting of: CHRLand C(RL)2; and the other of X2and X3is CH2or O. In some embodiments of Formula (IV-a2) or (IV-b2), X2is CH2; and X3is CHRL. In some embodiments, the compounds of Formula (V) are compounds of Formula (V- a2) or (V-b2): Formula (V-a2) Formula (V-b2) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X2is -O- or -CH2-; X1is CHRL; and X3is CHRLor C(RL)2, wherein: one pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring; and the remaining RLif present is C1-2alkyl optionally substituted with 1-3 F. In some embodiments of Formula (II-a2), (II-b2), (III-2), (IV-a2), (IV-b2), (V-a2), or (V-b2), R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom. In some embodiments of Formula (II-a2), (II-b2), (III-2), (IV-a2), (IV-b2), (V-a2), or (V-b2), R7is Rb1, wherein the Rb1is 5-6 membered heteroaryl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-2 Rg. In some embodiments of Formula (II-a1), (II-b1), (III-1), (IV-a1), (IV-b1), (V-a1), (V-b1), (II-a2), (II-b2), (III-2), (IV-a2), (IV-b2), (V-a2), or (V-b2), Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra. In some embodiments of Formula (II-a1), (II-b1), (III-1), (IV-a1), (IV-b1), (V-a1), . In some embodiments, the compound of Formula (II) is selected from the group consisting of Compound Nos.139, 139a, 139b, 139c, 158, 158a, 158b, 158c, 160, 160a, 161, 161a, 161b, 161c, 164, 164a, 164b, 170, 170a, 171, 171a, 171b, 171c, 176, 176a, 176b, 176c, 176d, 176e, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 180, 180a, 180b, 180c, 181, 181a, 183, 183a, 185, 185a, 190, 190a, 190b, 190c, 191, 191a, 191b, 191c, 191d, 192, 192a, 192b, 192c, 192d, and 192e, as depicted in Table C1, or a pharmaceutically acceptable salt thereof. For example, the compound of Formula (II) can be selected from the group consisting of Compound Nos.139, 139a, 139b, 139c, 158, 158a, 158b, 158c, 160, 160a, 161, 161a, 164, 164a, 164b, 170, 170a, 171, 171a, 176, 176a, 176b, 176c, 176d, 178, 178a, 178b, 179, 179a, 180, 180a, 181, and 181a as depicted in Table C1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (III) is selected from the group consisting of Compound Nos.158, 158a, 158b, 158c, 161, 161a, 161b, 161c, 176, 176a, 176b, 176c, 176d, 176e, 177, 177a, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 180, 180a, 180b, 180c, 184, 184b, 184c, 192, 192a, 192b, 192c, 192d, 192e, 194, and 194a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof. For example, the compound of Formula (III) can be selected from the group consisting of Compound Nos.158, 158a, 158b, 158c, 161, 161a, 176, 176a, 176b, 176c, 176d, 177, 177a, 178, 178a, 178b, 179, 179a, 180, and 180a as depicted in Table C1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (IV) is selected from the group consisting of Compound Nos.124, 124a, 124b, 124c, 124d, 124e, 124f, 125, 125a, 130, 130a, 130b, 130c, 131, 131a, 131b, 133, 133a, 133b, 133c, 134, 134a, 138, 138a, 148, 148a, 162, 162a, 162b, 162c, 162d, 163, 163a, 163b, 175, 175a, 176, 176a, 176b, 176c, 176d, 176e, 177, 177a, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 182, 182a, 182b, 182c, 182d, 193, and 193a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof. For example, the compound of Formula (IV) can be selected from the group consisting of Compound Nos. 124, 124a, 124b, 125, 125a, 130, 130a, 131, 131a, 133, 133a, 133b, 134, 134a, 138, 138a, 148, 148a, 162, 162a, 163, 163a, 175, and 175a as depicted in Table C1, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of Formula (V) is selected from the group consisting of Compound Nos. 172, 172a, 172b, and 172c as depicted in Table C1, or a pharmaceutically acceptable salt thereof. In some embodiments, compounds of Formula (A) (e.g., Formula (I)) are compounds of Formula (VI): or pharmaceutically acceptable salts thereof, wherein: R1is a 4-10 membered heterocyclyl substituted with -CN, –(C1-3alkylene)-CN, or – (C3-6cycloalkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; wherein each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of: (e) -C1-6alkoxy; (f) -C1-6 haloalkoxy; (g) -NRdRe; (h) C(=O)C1-6alkyl; (i) C(=O)C1-6 haloalkyl; (j) C(=O)OH; (k) C(=O)OC1-6alkyl; (l) C(=O)OC1-6 haloalkyl; (m) C(=O)N(Rf)2; (n) S(O)0-2(C1-6alkyl); (o) S(O)0-2(C1-6haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1- 2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-. In some embodiments of Formula (VI), R1is a 4-10 membered heterocyclyl substituted with -CN or –(C1-3alkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7. In some embodiments of Formula (VI), R1is a 6-8 membered heterocyclyl substituted with -CN or –(C1-3 alkylene)-CN on a ring carbon atom, wherein: the heterocyclyl has one ring nitrogen atom and 0-1 ring oxygen atom; and the heterocyclyl is further optionally substituted with 1-3 R7. In some embodiments of Formula (VI), each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI), R1is selected from the group consisting of: , wherein b3 is 0, 1, or 2. In some embodiments, each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc(e.g., C1-3 alkyl optionally substituted with 1-3 -F). In some embodiments, b3 is 0. For example, R1can Formula (VI). In some embodiments of Formula (VI), R9is -NRdReor OH (e.g., -NH2). In some embodiments, the compounds of Formula (VI) are compounds of Formula (VI- a): Formula (VI-a) or pharmaceutically acceptable salts thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI-a), b1 is 1 or 2. In some embodiments, the compounds of Formula (VI) are compounds of Formula (VI- b): Formula (VI-b) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI-b), R9is -NRdRe. In some embodiments, the compounds of Formula (VI) are compounds of Formula (VI- c): Formula (VI-c) or pharmaceutically acceptable salts thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2or CHRL. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2; and X2and X3are both CH2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), at least one (e.g., one) of X1, X2, and X3is selected from the group consisting of: CHRLand C(RL)2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2; and X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2, provided that 1-2 of X2and X3is independently CHRLor C(RL)2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2; X2is CH2; and X3is CHRL. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2; one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), X1is CH2; X2is -O-; and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), or (VI-c)), each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F. In some embodiments, the compounds of Formula (VI) are compounds of Formula (VI- d): Formula (VI-d) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that at least one of X1, X2, and X3is CHRLor C(RL)2; and further provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments, the compounds of Formula (VI) are compounds of Formula (VI- Formula (VI-e) or pharmaceutically acceptable salts thereof, wherein: X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that 2-3 of X1, X2, and X3are independently CHRLor C(RL)2; one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; and each additional RLis independently selected from the group consisting of: C1-3 alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI-d) or (VI-e), R9is NH2. In some embodiments of Formula (VI-d) or (VI-e), b1 is 1 or 2. In some embodiments of Formula (VI-d) or (VI-e), the selected from the group consisting of: b4 is 0 or 1; X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3 alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e)), Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra. In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), In some embodiments of Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), In some embodiments, the compound of Formula (VI) is selected from the group consisting of Compound Nos.149, 149a, 149b, 149c, 173, 173a, 174, 174a, 186, 186a, 186b, 186c, 187a, 187a, 188, 188a, 189, 189a, 191, 191a, 191b, 191c, 191d, 192, 192a, 192b, 192c, 192d, 192e, 195, and 195a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof. Certain examples of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II- a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))) compounds were synthesized using methods involving resolution of stereoisomeric mixture(s) (e.g., SFC separation of stereoisomers). In Table C1, the resolved stereogenic centers in these compounds are labelled with the “or1” and / or “or2” enhanced stereochemical notations. In some instances, the stereoisomeric resolutions were performed during the last step of the synthesis, thereby providing the individual stereoisomers of the Formula (A) compounds. Alternatively, in some other instances, the resolutions were performed on an intermediate or starting material, wherein each of the constituent stereoisomers of the intermediate or starting material could be separately subjected to the subsequent steps of the synthesis to provide the respective Formula (A) compounds as separate stereoisomers. A person of ordinary skill in the art would understand that, under either approach for stereoisomeric resolution, stereoisomers having both (R)- and (S)-configurations at a resolved stereogenic center are provided. See Table C3, wherein Table C1 compounds whose stereoisomers contain the or1 and / or or2 stereochemical notations are provided in non-stereogenic form, followed by the respective stereoisomers having the (R)- and (S)-configurations. Table C3

[0004] Also provided herein is a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutated KRas protein)) non-covalently bound with a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof. In some embodiments, Gly10 of the KRas protein interacts non-covalently with the R1group of the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, (e.g., via a hydrogen bond between the carbonyl of Gly10 and an OH group of R1and / or via a water mediated interaction between the NH group of Gly10 and an OH group of R1). Without wishing to be bound by theory, in some embodiments, the interaction between Gly10 of the KRas protein and the R1group of the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof , facilitates the inhibition of interaction between the KRas protein and Raf-RBD. In some embodiments, Arg68 of the KRas protein interacts non-covalently with the R1group of the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, (e.g., via a hydrogen bond between the guanidine of Arg68 and a CN group of R1). Without wishing to be bound by theory, in some embodiments, the interaction between Arg68 of the KRas protein and the R1group of the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II- a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, facilitates the inhibition of interaction between the KRas protein and Raf-RBD. Chemical definitions The term “halo” refers to fluoro (F), chloro (Cl), bromo (Br), or iodo (I). The term “oxo” refers to a divalent doubly bonded oxygen atom (i.e., “=O”). As used herein, oxo groups are attached to carbon atoms to form carbonyls. The term “alkyl” refers to a saturated acyclic hydrocarbon radical that may be a straight chain or branched chain, containing the indicated number of carbon atoms. For example, C1-10indicates that the group may have from 1 to 10 (inclusive) carbon atoms in it. Alkyl groups can either be unsubstituted or substituted with one or more substituents. Non-limiting examples include methyl, ethyl, iso-propyl, tert-butyl, n-hexyl. The term “saturated” as used in this context means only single bonds present between constituent carbon atoms and other available valences occupied by hydrogen and / or other substituents as defined herein. The term “haloalkyl” refers to an alkyl, in which one or more hydrogen atoms is / are replaced with an independently selected halo (e.g., -CF3, -CHF2, or -CH2F). The term “alkoxy” refers to an -O-alkyl radical (e.g., -OCH3). The term “alkylene” refers to a divalent alkyl (e.g., -CH2-). Similarly, terms such as “cycloalkylene” and “heterocyclylene” refer to divalent cycloalkyl and heterocyclyl respectively. For avoidance of doubt, in “cycloalkylene” and “heterocyclylene”, the two radicals can be on the same ring carbon atom (e.g., a geminal diradical such ) or on different ring atoms (e.g., ring carbon and / or nitrogen atoms (e.g., vicinal ring carbon and / or nitrogen atoms) The term “alkenyl” refers to an acyclic hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C2-6indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it. Alkenyl groups can either be unsubstituted or substituted with one or more substituents. The term “alkynyl” refers to an acyclic hydrocarbon chain that may be a straight chain or branched chain having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C2-6 indicates that the group may have from 2 to 6 (inclusive) carbon atoms in it. Alkynyl groups can either be unsubstituted or substituted with one or more substituents. The term “aryl” refers to a 6-20 carbon mono-, bi-, tri- or polycyclic group wherein at least one ring in the system is aromatic (e.g., 6-carbon monocyclic, 10-carbon bicyclic, or 14- carbon tricyclic aromatic ring system); and wherein 0, 1, 2, 3, or 4 atoms of each ring may be substituted by a substituent. Examples of aryl groups include phenyl, naphthyl, tetrahydronaphthyl, and the like. The term “cycloalkyl” as used herein refers to mono-, bi-, tri-, or polycyclic saturated or partially unsaturated hydrocarbon groups having, e.g., 3 to 20 ring carbons, preferably 3 to 15 ring carbons, and more preferably 3 to 12 ring carbons or 3-10 ring carbons or 3-6 ring carbons, wherein the cycloalkyl group may be optionally substituted. The term “saturated” as used in this context means only single bonds present between constituent carbon atoms. Examples of saturated cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Partially unsaturated cycloalkyl may have any degree of unsaturation provided that one or more double bonds is present in the cycloalkyl, none of the rings in the ring system are aromatic, and the partially unsaturated 30 cycloalkyl group is not fully saturated overall. Examples of partially unsaturated cycloalkyl include, without limitation, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Cycloalkyl may include multiple fused and / or bridged rings. Non-limiting examples of fused / bridged cycloalkyl includes: bicyclo[1.1.0]butyl, bicyclo[2.1.0]pentyl, bicyclo[1.1.1]pentyl, bicyclo[3.1.0]hexyl, bicyclo[2.1.1]hexyl, bicyclo[3.2.0]heptyl, bicyclo[4.1.0]heptyl, bicyclo[2.2.1]heptyl, bicyclo[3.1.1]heptyl, bicyclo[4.2.0]octyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, and the like. Cycloalkyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic cycloalkyls include spiro[2.2]pentyl, spiro[2.5]octyl, spiro[3.5]nonyl, spiro[3.5]nonyl, spiro[3.5]nonyl, spiro[4.4]nonyl, spiro[2.6]nonyl, spiro[4.5]decyl, spiro[3.6]decyl, spiro[5.5]undecyl, and the like. The term “heteroaryl”, as used herein, means a mono-, bi-, tri- or polycyclic group having 5 to 20 ring atoms, alternatively 5, 6, 9, 10, or 15 ring atoms; wherein at least one ring in the system contains one or more heteroatoms independently selected from the group consisting of N, O, S (inclusive of oxidized forms such as: (inclusive of oxidized forms such as: ) and at least one ring in the system is aromatic (but does not have to be a ring which contains a heteroatom, e.g. tetrahydroisoquinolinyl, e.g., tetrahydroquinolinyl). Heteroaryl groups can either be unsubstituted or substituted with one or more substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-c]pyridinyl, pyrazolo[3,4- b]pyridinyl, pyrazolo[3,4-c]pyridinyl, pyrazolo[4,3-c]pyridinyl, pyrazolo[4,3-b]pyridinyl, tetrazolyl, chromanyl, 2,3-dihydrobenzo[b][1,4]dioxinyl, benzo[d][1,3]dioxolyl, 2,3- dihydrobenzofuranyl, tetrahydroquinolinyl, 2,3-dihydrobenzo[b][1,4]oxathiinyl, isoindolinyl, and others. In some embodiments, the heteroaryl is selected from thienyl, pyridinyl, furyl, pyrazolyl, imidazolyl, isoindolinyl, pyranyl, pyrazinyl, and pyrimidinyl. For purposes of clarification, heteroaryl also includes aromatic lactams, aromatic cyclic ureas, or vinylogous analogs thereof, in which each ring nitrogen adjacent to a carbonyl is tertiary (i.e., all three valences are occupied by non-hydrogen substituents), such as one or more of pyridonyl (e.g.,

[0005] imidazolonyl (e.g., wherein each ring nitrogen adjacent to a carbonyl is tertiary (i.e., the oxo group (i.e., “=O”) herein is a constituent part of the heteroaryl ring). The term “heterocyclyl” refers to a mono-, bi-, tri-, or polycyclic saturated or partially unsaturated ring system with 3-15 ring atoms (e.g., 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-15 membered tricyclic ring system) having 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic or polycyclic, the heteroatoms selected from O, N, S (inclusive of oxidized forms such as: and P (inclusive of oxidized forms such as: ) (e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, S, or P if monocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3 atoms of each ring may be substituted by a substituent. The term “saturated” as used in this context means only single bonds present between constituent ring atoms and other available valences occupied by hydrogen and / or other substituents as defined herein. Examples of saturated heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like. Partially unsaturated heterocyclyl groups may have any degree of unsaturation provided that one or more double bonds is present in the heterocyclyl, none of the rings in the ring system are aromatic, and the partially unsaturated heterocyclyl group is not fully saturated overall. Examples of partially unsaturated heterocyclyl groups include, without limitation, tetrahydropyridyl, dihydropyrazinyl, dihydropyridyl, dihydropyrrolyl, dihydrofuranyl, dihydrothiophenyl. Heterocyclyl may include multiple fused and bridged rings. Non-limiting examples of fused / bridged heteorocyclyl includes: 2-azabicyclo[1.1.0]butyl, 2-azabicyclo[2.1.0]pentyl, 2- azabicyclo[1.1.1]pentyl, 3-azabicyclo[3.1.0]hexyl, 5-azabicyclo[2.1.1]hexyl, 3-25 azabicyclo[3.2.0]heptyl, octahydrocyclopenta[c]pyrrole, 3-azabicyclo[4.1.0]heptyl, 7- azabicyclo[2.2.1]heptyl, 6-azabicyclo[3.1.1]heptyl, 7-azabicyclo[4.2.0]octyl, 2- azabicyclo[2.2.2]octyl, 3-azabicyclo[3.2.1]octyl, 2-oxabicyclo[1.1.0]butyl, 2- oxabicyclo[2.1.0]pentyl, 2-oxabicyclo[1.1.1]pentyl, 3-oxabicyclo[3.1.0]hexyl, 5- oxabicyclo[2.1.1]hexyl, 3-oxabicyclo[3.2.0]heptyl, 3-oxabicyclo[4.1.0]heptyl, 7- oxabicyclo[2.2.1]heptyl, 6-oxabicyclo[3.1.1]heptyl, 7-oxabicyclo[4.2.0]octyl, 2- oxabicyclo[2.2.2]octyl, 3-oxabicyclo[3.2.1]octyl, and the like. Heterocyclyl also includes spirocyclic rings (e.g., spirocyclic bicycle wherein two rings are connected through just one atom). Non-limiting examples of spirocyclic heterocyclyls include 2-azaspiro[2.2]pentyl, 4- azaspiro[2.5]octyl, 1-azaspiro[3.5]nonyl, 2-azaspiro[3.5]nonyl, 7-azaspiro[3.5]nonyl, 2- azaspiro[4.4]nonyl, 6-azaspiro[2.6]nonyl, 1,7-diazaspiro[4.5]decyl, 7-azaspiro[4.5]decyl 2,5- diazaspiro[3.6]decyl, 3-azaspiro[5.5]undecyl, 2-oxaspiro[2.2]pentyl, 4-oxaspiro[2.5]octyl, 1- oxaspiro[3.5]nonyl, 2-oxaspiro[3.5]nonyl, 7-oxaspiro[3.5]nonyl, 2-oxaspiro[4.4]nonyl, 6- oxaspiro[2.6]nonyl, 1,7-dioxaspiro[4.5]decyl, 2,5-dioxaspiro[3.6]decyl, 1- oxaspiro[5.5]undecyl, 3-oxaspiro[5.5]undecyl, 3-oxa-9-azaspiro[5.5]undecyl and the like. As used herein, when a ring is described as being “partially unsaturated”, it means the ring has one or more additional degrees of unsaturation (in addition to the degree of unsaturation attributed to the ring itself; e.g., one or more double or triple bonds between constituent ring atoms), provided that the ring is not aromatic. Examples of such rings include: cyclopentene, cyclohexene, cycloheptene, dihydropyridine, tetrahydropyridine, dihydropyrrole, dihydrofuran, dihydrothiophene, and the like. For the avoidance of doubt, and unless otherwise specified, for rings and cyclic groups (e.g., aryl, heteroaryl, heterocyclyl, heterocycloalkenyl, cycloalkenyl, cycloalkyl, and the like described herein) containing a sufficient number of ring atoms to form bicyclic or higher order ring systems (e.g., tricyclic, polycyclic ring systems), it is understood that such rings and cyclic groups encompass those having fused rings, including those in which the points of fusion are located (i) on adjacent ring atoms (e.g., [x.x.0] ring systems, in which 0 represents a zero atom bridge (e.g., (ii) a single ring atom (spiro-fused ring systems) , (iii) a contiguous array of ring atoms (bridged ring systems In addition, atoms making up the compounds of the present embodiments are intended to include all isotopic forms of such atoms. Isotopes, as used herein, include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include13C and14C. In addition, the compounds generically or specifically disclosed herein are intended to include all tautomeric forms. Thus, by way of example, a compound containing the moiety: encompasses the tautomeric form containing the moiety: . Similarly, a pyridinyl or pyrimidinyl moiety that is described to be optionally substituted with hydroxyl encompasses pyridone or pyrimidone tautomeric forms. The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g., mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound. Methods of Treatment Indications Provided herein are methods for inhibiting a KRas protein. For example, provided herein are inhibitors of a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutant KRas protein (e.g., a KRas G12D mutant protein, a KRas G12R mutant protein, or a KRas G12V mutant protein))) useful for treating or preventing diseases or disorders associated with the KRas dysregulation (i.e., a KRas-associated disease or disorder), such as a cardiovascular disease, an inflammatory and / or autoimmune disease, or a cancer (e.g., a KRas-associated cancer). The term "KRas-associated disease or disorder" as used herein refers to diseases or disorders associated with or having a dysregulation of a KRAS gene, a KRas protein, or the expression or activity or level of any (e.g., one or more) of the same (e.g., any of the types of dysregulations of a KRAS gene, a KRas protein, or the expression or activity or level of any of the same described herein). Non-limiting examples of a KRas-associated disease or disorder include, for example, cancer, a cardiovascular disease (e.g., arteriovenous malformations), endometriosis, and an inflammatory and / or autoimmune disease (e.g., a nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis). See, e.g., Adashek et al. Genome Med. 2020; 12: 16, doi: 10.1186 / s13073-020-0714-y; Niemela et al. Blood. 2011; 117(10):2883-6, doi: 10.1182 / blood-2010-07-295501; Nosan et al. Croat Med J.2013; 54(6): 574–578, doi: 10.3325 / cmj.2013.54.574; and Messina et al. Small GTPases 11.5 (2020): 312- 319, 10.1080 / 21541248.2018.1502591. The term “mutant KRas-associated disease or disorder” as used herein refers to diseases or disorders associated with or having a KRas mutation (e.g., a KRAS gene having a mutation corresponding to a mutation in a KRas protein and / or a KRas protein having a mutation). Non- limiting examples of a mutant KRas-associated disease or disorder include, for example, cancer, a cardiovascular disease (e.g., arteriovenous malformations), endometriosis, and an inflammatory and / or autoimmune disease (e.g., a nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis). See, e.g., Adashek et al. Genome Med. 2020; 12: 16, doi: 10.1186 / s13073-020-0714-y; Niemela et al. Blood.2011; 117(10):2883-6, doi: 10.1182 / blood- 2010-07-295501; Nosan et al. Croat Med J. 2013; 54(6): 574–578, doi: 10.3325 / cmj.2013.54.574; and Messina et al. Small GTPases 11.5 (2020): 312-319, 10.1080 / 21541248.2018.1502591. The phrase “dysregulation of a KRAS gene, a KRas protein, or the expression or activity or level of any of the same” refers to a genetic mutation (e.g., a mutation in a KRAS gene that results in the expression of a KRas protein that includes a deletion of at least one amino acid as compared to a wild type KRas protein, a mutation in a KRAS gene that results in the expression of a KRas protein with one or more point mutations as compared to a wild type KRas protein, a mutation in a KRAS gene that results in the expression of a KRas protein with at least one inserted amino acid as compared to a wild type KRas protein, a gene duplication that results in an increased level of KRas protein in a cell, or a mutation in a regulatory sequence (e.g., a promoter and / or enhancer) that results in an increased level of KRas protein in a cell); an alternative spliced version of a KRas mRNA that results in a KRas protein having a deletion of at least one amino acid in the KRas protein as compared to the wild type KRas protein; or increased expression (e.g., increased levels) of a wild type KRas protein in a mammalian cell due to aberrant cell signaling and / or dysregulated autocrine / paracrine signaling (e.g., as compared to a control non-cancerous cell). As an example, a dysregulation of a KRAS gene, a KRas protein, or expression or activity, or level of any of the same, can be a mutation in a KRAS gene that encodes a KRas protein that has low GTPase activity and / or has increased signaling activity as compared to a protein encoded by a KRAS gene that does not include the mutation. As another example, a dysregulation of a KRAS gene, a KRas protein, or expression or activity, or level of any of the same, can be a KRas amplification. In some embodiments, a KRas amplification is an amplification of the wild type KRas. In some embodiments, a KRas amplification is an amplification of a mutant KRas. A “dysregulated KRas protein” as used herein refers to (i) a KRas protein having a mutation (e.g., a deletion of at least one amino acid as compared to a wild type KRas protein, one or more point mutations as compared to a wild type KRas protein, or an insertion of at least one amino acid as compared to a wild type KRas protein); (ii) a KRas protein resulting from a gene duplication event, e.g., of the gene encoding the KRas protein (e.g., the wild type KRas protein), thus resulting in an increased level and / or activity of the KRas protein (e.g., the wild type KRas protein) in a cell; (iii) a KRas protein resulting from a mutation in a regulatory sequence (e.g., a promoter and / or enhancer) that can also result in an increased level and / or activity of the KRas protein (e.g., the wild type KRas protein) in a cell); (iv) a KRas protein resulting from an alternative spliced version of a KRas mRNA that results in a KRas protein having a deletion of at least one amino acid in the KRas protein as compared to the wild type KRas protein); or (v) a KRas protein resulting from increased expression (e.g., increased levels) of a wild type KRas protein in a mammalian cell due to aberrant cell signaling and / or dysregulated autocrine / paracrine signaling (e.g., as compared to a control non-cancerous cell). In some embodiments, a dysregulated KRas protein is a dysregulated human KRas protein. A “mutant KRas protein” as used herein refers to a KRas protein including a substitution, an insertion, a deletion, a truncation and / or a fusion relative to the wild type human KRas sequence shown in SEQ ID NO:1. For example, a mutant human KRas protein includes a substitution at any amino acid position (relative to SEQ ID NO: 1). A “KRas G12X mutant protein” as used herein refers to a KRas protein including substitution of a glycine to any other amino acid at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12A mutant protein” as used herein refers to a KRas protein including a glycine to alanine substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12C mutant protein” as used herein refers to a KRas protein including a glycine to cysteine substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12D mutant protein” as used herein refers to a KRas protein including a glycine to aspartic acid substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12R mutant protein” as used herein refers to a KRas protein including a glycine to arginine substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12S mutant protein” as used herein refers to a KRas protein including a glycine to serine substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G12V mutant protein” as used herein refers to a KRas protein including a glycine to valine substitution at the twelfth amino acid position (relative to SEQ ID NO: 1). A “KRas G13X mutant protein” as used herein refers to a KRas protein including substitution of a glycine to any other amino acid at the thirteenth amino acid position (relative to SEQ ID NO: 1). A “KRas G13C mutant protein” as used herein refers to a KRas protein including a glycine to cysteine substitution at the thirteenth amino acid position (relative to SEQ ID NO: 1). A “KRas G13D mutant protein” as used herein refers to a KRas protein including a glycine to aspartic acid substitution at the thirteenth amino acid position (relative to SEQ ID NO: 1). A “KRas G13V mutant protein” as used herein refers to a KRas protein including a glycine to valine substitution at the thirteenth amino acid position (relative to SEQ ID NO: 1). A “KRas Q61X mutant protein” as used herein refers to a KRas protein including substitution of a glutamine to any other amino acid at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61E mutant protein” as used herein refers to a KRas protein including a glutamine to glutamic acid substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61H mutant protein” as used herein refers to a KRas protein including a glutamine to histidine substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61K mutant protein” as used herein refers to a KRas protein including a glutamine to lysine substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61L mutant protein” as used herein refers to a KRas protein including a glutamine to leucine substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61P mutant protein” as used herein refers to a KRas protein including a glutamine to proline substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas Q61R mutant protein” as used herein refers to a KRas protein including a glutamine to arginine substitution at the sixty-first amino acid position (relative to SEQ ID NO: 1). A “KRas inhibitor” as used herein includes any compound exhibiting KRas protein inactivation activity (e.g., inhibiting or decreasing KRas signaling activity). In some embodiments, a KRas inhibitor as described herein has an IC50 value of 1 µM or less in a nucleotide exchange assay as described herein, an IC50 value of 1 µM or less in a Raf kinase interaction assay as described herein, or both. In some embodiments, a KRas inhibitor inhibits the signaling activity of a wild type KRas protein. In some embodiments, a KRas inhibitor inhibits the signaling activity of a dysregulated KRas protein, for example, resulting in a decrease in activated Raf or other downstream effectors, such as ERK. In some embodiments, a KRas inhibitor inhibits the signaling activity of a mutant KRas protein. In some embodiments, a KRas inhibitor inhibits both the signaling activity of a wild-type KRas protein and the signaling activity of one or more mutant KRas proteins and can be termed a “pan KRas inhibitor”. In some embodiments, a KRas inhibitor inhibits one or more mutant KRas proteins, and such a KRas inhibitor can be termed a “mutant KRas inhibitor”, and also termed by the mutant(s) it inhibits. For example, a KRas inhibitor that inhibits KRas G12R mutant protein could be termed a “KRas G12R inhibitor”. As another example, a KRas inhibitor that inhibits both KRas G12C mutant protein and KRas G12D mutant protein could be termed a “KRas G12C inhibitor” and / or a “KRas G12D inhibitor”. In some embodiments, a “mutant KRas inhibitor” inhibits two or more mutant KRas proteins and can be termed a “pan mutant KRas inhibitor”. In some embodiments, a pan mutant KRas inhibitor inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. For example, a “KRas G12X inhibitor” can inhibit two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. As yet another example, a KRas inhibitor that inhibits a KRas G13D mutant protein could be termed a “KRas G13D inhibitor”. In some embodiments, a KRas inhibitor can inhibit a KRas protein having one or more mutations, and such a KRas inhibitor can be termed a “mutant KRas inhibitor” whether or not the mutant KRas inhibitor also inhibits wild type KRas protein. In some embodiments, a KRas inhibitor is a mutant KRas inhibitor. In some embodiments, a KRas inhibitor is an allosteric inhibitor. Compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I- a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are KRas inhibitors. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a mutant KRas inhibitor. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12V mutant protein, or a combination thereof. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRas G12V mutant protein, or both. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12R mutant protein, a KRas G12V mutant protein, or both. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a KRas G12X inhibitor. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits four or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits five or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits four or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRAS G12V mutant protein, or both. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12C mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, does not inhibit a KRas G12C mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, does not inhibit a KRas G12D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12S mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a KRas G13X inhibitor. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas G13V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas G13V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas G13V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G13C mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G13D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G13V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a KRas Q61X inhibitor. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits four or more mutant KRas proteins selected from the group consisting of: a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits five or more mutant KRas proteins selected from the group consisting of: a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61E mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61K mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61P mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12X mutant protein, a KRas G13X mutant protein, and a KRas Q61X mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12X mutant protein, a KRas G13X mutant protein, and a KRas Q61X mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant human KRas proteins selected from the group consisting of: a KRas G12X mutant protein, a KRas G13X mutant protein, and a KRas Q61X mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12X mutant protein, a KRas G13X mutant protein, and a KRas Q61X mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits four or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, five or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12V mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12V mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12V mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I- c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a bladder cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12V mutant protein, and a KRas G13D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12V mutant protein, and a KRas G13D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12V mutant protein, and a KRas G13D mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRas G12V mutant protein, or both. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a cervical cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a colorectal cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating an endometrial cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, and a KRas Q61H mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, a KRas G12V mutant protein, or both. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating an esophageal or stomach cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas Q61E mutant protein, a KRas Q61H mutant protein, a KRas Q61K mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a leukemia. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas a KRas Q61K mutant protein, a KRas Q61L mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas a KRas Q61K mutant protein, a KRas Q61L mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I- c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G13D mutant protein, a KRas G13V mutant protein, a KRas a KRas Q61K mutant protein, a KRas Q61L mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12C mutant protein, a KRas G12D mutant protein, and a KRas G12R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein, and a KRas G12R mutant protein, or both. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a melanoma. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas G13D mutant protein, a KRas Q61H mutant protein, and a KRas Q61L mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I- c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12D mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a lung cancer (e.g., non-small cell lung cancer). In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas Q61H mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas Q61H mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas G13C mutant protein, a KRas Q61H mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12C mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a pancreatic cancer. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, a KRas G12V mutant protein, a KRas Q61L mutant protein, a KRas Q61P mutant protein, and a KRas Q61R mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI- d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits three or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, a KRas G12S mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI- a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits one or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits two or more mutant KRas proteins selected from the group consisting of: a KRas G12A mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12A mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein. In some such embodiments, the compounds of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or pharmaceutically acceptable salts thereof, are useful for treating a testicular cancer (e.g., seminoma). In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can bind to a KRas protein in the GTP-bound state. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can bind selectively to a KRas protein in the GTP-bound state. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can bind to a KRas protein in the GDP-bound state. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can bind selectively to a KRas protein in the GDP-bound state. An exemplary sequence of mature human KRas protein is shown below (UniProtKB entry P01116) (SEQ ID NO: 1) MTEYKLVVVG AGGVGKSALT IQLIQNHFVD EYDPTIEDSY RKQVVIDGET CLLDILDTAG QEEYSAMRDQ YMRTGEGFLC VFAINNTKSF EDIHHYREQI KRVKDSEDVP MVLVGNKCDL PSRTVDTKQA QDLARSYGIP FIETSAKTRQ RVEDAFYTLV REIRQYRLKK ISKEEKTPGC VKIKKCIIM As used herein, “selective” or “selectively”, when referring to an assayed compound, indicates at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) superior performance in an assay (e.g., binding affinity and / or potency) for a specified condition with reference to a comparator protein variant in the assay. For example, if a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I- a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, binds “selectively” to a KRas G12X mutant protein over the wild type KRas protein as determined by a surface plasmon resonance (SPR) assay, then the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, has at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) smaller KDvalue for any one or more KRas mutant proteins selected from the group consisting of the KRas G12X mutant proteins than for the wild type KRas protein when measured by the SPR assay. As a further example, if a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, “selectively” reduces the viability the KRas G12V mutant protein-expressing cells over the cells expressing KRas G12C protein as determined by a cell proliferation assay, then the compound has at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) EC50 value for the KRas G12V mutant protein-expressing cells than for the KRas G12C protein-expressing cells when measured by the cell proliferation assay. In another example, if a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, “selectively” inhibits a KRas G13X mutant protein over the wild type KRas protein as determined by a Raf kinase interaction assay, then the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, has at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) smaller IC50 value for the KRas G13X protein than for the wild type KRas protein when measured by the Raf kinase interaction assay. As a further example, if a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, “selectively” inhibits the KRas G12R mutant protein over the wild type KRas protein as determined by a nucleotide exchange assay, then the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I- a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III- 1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V- a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, has at least a 5-fold (e.g., at least a 10-fold, at least a 25-fold, at least a 50-fold, or at least a 100-fold) smaller IC50 value for the KRas G12R mutant protein than for the wild type KRas protein when measured by the nucleotide exchange assay. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a pan mutant KRas inhibitor (i.e., can inhibit two or more mutant KRas proteins (e.g., two or more of a KRas G12A mutant protein, a KRas G12D mutant protein, a KRas G12R mutant protein, and a KRas G12V mutant protein)). For example, such a compound can inhibit each mutant KRas protein (e.g., two or more mutant KRas proteins) with an IC50of less than 1 µM (e.g., less than 750 nM, less than 500 nM, or less than 200 nM). As another example, such a compound can inhibit ERK phosphorylation in cell lines each expressing a mutant KRas protein with an independent IC50of less than 1 µM (e.g., less than 750 nM, less than 500 nM, or less than 200 nM) in at least of the two cell lines. For example, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I- a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III- 2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV- b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can inhibit ERK phosphorylation in a cell line expressing a KRas G12R mutant protein with an IC50 of less than 1 µM, and the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I- b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II- b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, can inhibit ERK phosphorylation in a cell line expressing a KRas G12V mutant protein with an IC50of less than 1 µM. In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II- b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV- b), (IV-c), (IV-a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V- b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, is a pan KRas inhibitor (i.e., the compound can inhibit wild type KRas and one or more mutant KRas proteins). In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV- b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, does not inhibit certain KRas proteins (e.g., wild type KRas or one or more dysregulated KRas proteins). For example, such a compound can inhibit the interaction between a KRas protein it does not inhibit (e.g., a dysregulated KRas protein) and one or more Raf proteins with an IC50of 1 µM or greater than 1 µM (e.g., greater than 2 µM, greater than 5 µM, greater than 10 µM, or greater than 30 µM). As another example, such a compound can inhibit ERK phosphorylation in cell lines expressing the KRas protein it does not inhibit (e.g., a dysregulated KRas protein) with an IC50of 1 µM or greater than 1 µM (e.g., greater than 2 µM, greater than 5 µM, greater than 10 µM, or greater than 30 µM). In some embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I- a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV- a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits a KRas G12D mutant protein and a KRas G12V mutant protein. In some such embodiments, a compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I-b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), or (II-b2)), Formula (III) (e.g., Formula (III-1) or (III-2)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV- a1), (IV-b1), (IV-a2), or (IV-b2)), or Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V- c), (V-d), (V-b1), (V-a2), or (V-b2)), or Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or a pharmaceutically acceptable salt thereof, inhibits ERK phosphorylation in a cell line expressing a KRas G12D mutant protein (e.g., AGS, ASPC1, GP2D, LS180, Panc04.03, HPAFII, Panc02.03, A427, and HPAC) with an IC50 that is within about 10-fold, i.e., within about 10-fold less or within about 10-fold more (e.g., within about 9-fold less or within about 9-fold more, within about 8-fold less or within about 8-fold more, within about 7-fold less or within about 7-fold more, within about 6-fold less or within about 6-fold more, within about 5-fold less or within about 5-fold more, or within about 2-fold less or within about 2-fold more) of the IC50measured for inhibition of ERK phosphorylation by the compound in a cell line expressing a KRas G12V mutant protein (e.g., SW620, H727, CFPAC1, CAPAN1, RKN, H441, and SW480). For example, if the compound of Formula (A) (e.g., Formula (I) (e.g., Formula (I-a1), (I-a2), (I-a3), (I-a4), (I-a5), (I-b1), (I-b2), (I-b3), (I- b4), (I-b5), or (I-c1)), Formula (II) (e.g., Formula (II-a), (II-b), (II-a1)...

Claims

WHAT IS CLAIMED IS:

1. A compound of Formula (III):Formula (III) or a pharmaceutically acceptable salt thereof, wherein: R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii), wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; b4 is 0 or 1; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring;Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of:each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3;each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1- 2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-.

2. The compound of claim 1, wherein R9is -NH2; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc.

3. A compound of Formula (II):Formula (II) or a pharmaceutically acceptable salt thereof, wherein:30R1is selected from the group consisting of:(i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii), wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 1 or 2; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and(b) -NRdRe; each Rais independently selected from the group consisting of:each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl),and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-.

4. The compound of claim 3, wherein the compound is a compound of Formula (II-a):Formula (II-a) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (II-b):Formula (II-b) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc.

5. The compound of any one of claims 1-4, wherein X1is CH2 or CHRL.

6. The compound of any one of claims 1-5, wherein X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2.

7. The compound of any one of claims 1-6, wherein X1is CH2; and X2and X3are both CH2; or wherein at least one (e.g., one) of X1, X2, and X3is selected from the group consisting of: CHRLand C(RL)2; or wherein X1is CH2; and X2and X3are independently selected from the group consisting of: CH2, CHRL, and C(RL)2, provided that 1-2 of X2and X3is independently CHRLor C(RL)2; or wherein X1is CH2; X2is CH2; and X3is CHRL.

8. The compound of any one of claims 1-5, wherein one of X2and X3is -O-; and the other of X2and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2; optionally wherein X2is -O-; and X3is selected from the group consisting of: CH2, CHRL, and C(RL)2.

9. The compound of any one of claims 1-8, wherein each RLis independently selected from the group consisting of: CH3, CF3, CHF2, and CH2F.

10. The compound of claim 3, wherein thefrom the group consisting of:, wherein:b4 is 0 or 1; X2is -O- or -CH2-; X3is -CH2- or -CHRL-, wherein RLis C1-3 alkyl (e.g., methyl); and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc;Formula (IV) or a pharmaceutically acceptable salt thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that at least one of X1, X2, and X3is CHRLor C(RL)2; further provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc;R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii), wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of:(h) C(=O)C1-6alkyl; (i) C(=O)C1-6 haloalkyl; (j) C(=O)OH; (k) C(=O)OC1-6alkyl; (l) C(=O)OC1-6 haloalkyl; (m) C(=O)N(Rf)2; (n) S(O)0-2(C1-6alkyl); (o) S(O)0-2(C1-6 haloalkyl); (p) S(O)1-2N(Rf)2; and (q) C1-6alkyl, C2-6alkenyl, or C2-6alkynyl, each optionally substituted with 1-6 Rc; each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-.

12. The compound of claim 11, wherein the compound is a compound of Formula (IV-a):Formula (IV-a) or a pharmaceutically acceptable salt thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (IV-b):Formula (IV-b) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (IV-c):Formula (IV-c) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc.

13. A compound of Formula (V):Formula (V) or a pharmaceutically acceptable salt thereof, wherein: X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that 2-3 of X1, X2, and X3are independently CHRLor C(RL)2; one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6 cycloalkyl ring; and each additional RLis independently selected from the group consisting of: C1-3 alkoxy, -F, CN, and C1-3alkyl optionally substituted with 1-3 Rc; b1 is 0, 1 or 2; R9is selected from the group consisting of: H, OH, NRdRe, and halo; each R10is independently selected from the group consisting of Raand Rb; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii), wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb;Y2is a bond or a straight-chain C1-6 alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6alkoxy, C1-6haloalkoxy, C1-6alkyl, and C1-6haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of:each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1,wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3alkylene; and each Rb1is independently selected from the group consisting of: C3-10 cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NRdRe, C(=O)C1-6alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6haloalkyl, C(=O)OC1-6alkyl, C(=O)OC1-6haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6 alkyl), S(O)1-2(C1-6 haloalkyl), S(O)1-2N(Rf)2, and C1-6 alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-.

14. The compound of claim 13, wherein the compound is a compound of Formula (V-a):Formula (V-a) or a pharmaceutically acceptable salt thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; orwherein the compound is a compound of Formula (IV-b):Formula (V-b) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (V-c) or Formula (V-d):or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; the pair of RL1taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring, and RL2is C1-2alkyl optionally substituted with 1-3 F.

15. The compound of any one of claims 1-14, wherein Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra; optionally wherein16. The compound of any one of claims 1-15, wherein R1is, wherein b2 is 0, 1, or 2, and A1and A2are independently selected from the group consisting of: N, CH, and CR7; or.

17. The compound of any one of claims 1-16, whereinis selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1.

18. The compound of claim 17, wherein R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3 alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom; or optionally whereinR7is C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh.

19. The compound of any one of claims 1-16, wherein, wherein R7aand R7bare independently selected R7.

20. The compound of claim 19, wherein R7ais selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1; and R7bis -halo, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein R7ais selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3 alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom.

21. The compound of any one of claims 1-15, wherein R1is a 7-10 (e.g., 7) membered heterocyclyl having one ring nitrogen atom, one ring oxygen atom, and no additional ring heteroatoms, wherein the 7-10 membered heterocyclyl is optionally substituted with 1-4 R7.

22. The compound of claim 21, whereinoptionally substituted with 1- 4 R7at one or more ring carbon atoms23. The compound of claim 22, wherein each R7is independently selected from thegroup consisting of: -OH; -CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc, wherein: each Rcis independently selected from the group consisting of: -F, -OH, and -CN.

24. The compound of claim 1, wherein the compound is a compound of Formula (III-1):Formula (III-1) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2.

25. The compound of claim 24, wherein R9is NRdRe(e.g., -NH2).

26. The compound of claim 3, wherein the compound is a compound of Formula (II-a1) or (II-b1):Formula (II-a1)Formula (II-b1) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2.

27. The compound of claim 11, wherein the compound is a compound of Formula (IV-a1) or (IV-b1):Formula (IV-a1)Formula (IV-b1) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X1is CH2; one of X2and X3is independently selected from the group consisting of: CHRLand C(RL)2; and the other of X2and X3is CH2 or O.

28. The compound of claim 27, wherein X2is CH2; and X3is CHRL.

29. The compound of claim 13, wherein the compound is a compound of Formula (V-a1) or (V-b1):Formula (V-a1)Formula (V-b1) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; b3 is 0, 1, 2, or 3; X2is -O- or -CH2-; X1is CHRL; and X3is CHRLor C(RL)2, wherein: one pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring; and the remaining RLif present is C1-2 alkyl optionally substituted with 1-3 F.

30. The compound of any one of claims 26-29, wherein b3 is 0; or wherein b3 is 1 or 2; and each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3alkyl optionally substituted with 1-3 Rc, wherein each Rcis independently selected from the group consisting of: -F, -OH, and -CN.

31. The compound of claim 1, wherein the compound is a compound of Formula (III-2):Formula (III-2) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2.

32. The compound of claim 31, wherein R9is NRdRe(e.g., -NH2).

33. The compound of claim 3, wherein the compound is a compound of Formula (II-a2) or (II-b2):Formula (II-b2) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1;each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, - C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; and X2and X3are independently selected from the group consisting of: O, CH2, CHRL, and C(RL)2.

34. The compound of claim 11, wherein the compound is a compound of Formula (IV-a2) or (IV-b2):Formula (IV-b2) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1; X1is CH2; one of X2and X3is independently selected from the group consisting of: CHRLand C(RL)2; and the other of X2and X3is CH2 or O.

35. The compound of claim 34, wherein X2is CH2; and X3is CHRL.

36. The compound of claim 13, wherein the compound is a compound of Formula (V-a2) or (V-b2):Formula (V-b2) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; b1 is 0, 1, or 2; each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; R7is selected from the group consisting of: C(=O)N(Rf)2, C(O)N(C1-3 alkyl)Rb1, -C(O)N(H)Rb1, Rb1, and C(O)Rb1; X2is -O- or -CH2-; X1is CHRL; and X3is CHRLor C(RL)2, wherein: one pair of RLon different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-4 cycloalkyl ring; and the remaining RLif present is C1-2 alkyl optionally substituted with 1-3 F.

37. The compound of any one of claims 31-36, wherein R7is selected from the group consisting of: (a) C(=O)N(Rf)2, wherein each Rfis independently H or C1-3alkyl optionally substituted with 1-3 Rh; (b) C(O)N(C1-3 alkyl)Rb1or -C(O)N(H)Rb1, wherein: Rb1is C3-6 cycloalkyl or 4-6 membered heterocyclyl, each of which is optionally substituted with 1-3 Rg; and (c) C(O)Rb1, wherein Rb1is 4-10 membered heterocyclyl optionally substituted with 1-3 Rg, wherein Rb1is attached to the C(O) via a ring nitrogen atom.

38. The compound of claim 1, wherein the compound of Formula (III) is selected from the group consisting of Compound Nos.158, 158a, 158b, 158c, 161, 161a, 161b, 161c, 176, 176a, 176b, 176c, 176d, 176e, 177, 177a, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 180, 180a, 180b, 180c, 184, 184b, 184c, 192, 192a, 192b, 192c, 192d, 192e, 194, and 194a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof.

39. The compound of claim 3, wherein the compound of Formula (II) is selected from the group consisting of Compound Nos.139, 139a, 139b, 139c, 158, 158a, 158b, 158c, 160, 160a, 161, 161a, 161b, 161c, 164, 164a, 164b, 170, 170a, 171, 171a, 171b, 171c, 176, 176a, 176b, 176c, 176d, 176e, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 180, 180a, 180b, 180c, 181, 181a, 183, 183a, 185, 185a, 190, 190a, 190b, 190c, 191, 191a, 191b, 191c, 191d, 192, 192a, 192b, 192c, 192d, and 192e, as depicted in Table C1, or a pharmaceutically acceptable salt thereof.

40. The compound of claim 11, wherein the compound of Formula (IV) is selected from the group consisting of Compound Nos. 124, 124a, 124b, 124c, 124d, 124e, 124f, 125, 125a, 130, 130a, 130b, 130c, 131, 131a, 131b, 133, 133a, 133b, 133c, 134, 134a, 138, 138a,148, 148a, 162, 162a, 162b, 162c, 162d, 163, 163a, 163b, 175, 175a, 176, 176a, 176b, 176c, 176d, 176e, 177, 177a, 178, 178a, 178b, 179, 179a, 179b, 179d, 179e, 179f, 182, 182a, 182b, 182c, 182d, 193, and 193a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof.

41. The compound of claim 13, wherein the compound of Formula (V) is selected from the group consisting of Compound Nos.172, 172a, 172b, and 172c as depicted in Table C1, or a pharmaceutically acceptable salt thereof.

42. A compound of Formula (VI):Formula (VI) or a pharmaceutically acceptable salt thereof, wherein: R1is a 4-10 membered heterocyclyl substituted with -CN, –(C1-3 alkylene)-CN, or – (C3-6cycloalkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; wherein each R7is independently selected from the group consisting of Raand Rb; X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; b1 is 0, 1, or 2; R9is selected from the group consisting of: H, NRdRe, -OH, and halo; each R10is independently selected from the group consisting of Raand Rb; each RLis independently selected from the group consisting of C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring;Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6 cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of:each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein:b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1- 6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6alkyl), S(O)0-2(C1-6haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3alkyl, C1-3haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6alkoxy, -C1-6haloalkoxy, -NH2, -N(H)(C1-3alkyl), and -N(C1-3alkyl)2-.

43. The compound of claim 42, wherein R1is a 4-10 membered heterocyclyl substituted with -CN or –(C1-3alkylene)-CN on a ring carbon atom, wherein the heterocyclyl is further optionally substituted with 1-3 R7; optionally wherein R1is a 6-8 membered heterocyclyl substituted with -CN or –(C1-3 alkylene)-CN on a ring carbon atom, wherein: the heterocyclyl has one ring nitrogen atom and 0-1 ring oxygen atom; and the heterocyclyl is further optionally substituted with 1-3 R7; optionally wherein each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3 alkyl optionally substituted with 1-3 Rc.

44. The compound of any one of claims 42 or 43, wherein R1is selected from thegroup consisting of:, wherein b3 is 0, 1, or 2.

45. The compound of claim 44, wherein each R7is independently selected from the group consisting of: -OH; -CN; -F; and C1-3 alkyl optionally substituted with 1-3 Rc(e.g., C1-3 alkyl optionally substituted with 1-3 -F).

46. The compound of claim 44 or 45, wherein b3 is 0.

47. The compound of any one of claims 42-46, wherein R9is -NRdReor OH (e.g., -NH2).

48. The compound of any one of claims 42-47, wherein the compound of Formula (VI) is a compound of Formula (VI-a):Formula (VI-a) or a pharmaceutically acceptable salt thereof, wherein: each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein the compound of Formula (VI) is a compound of Formula (VI-b):Formula (VI-b) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; or wherein the compound of Formula (VI) is a compound of Formula (VI-c):Formula (VI-c) or a pharmaceutically acceptable salt thereof, wherein: b4 is 0 or 1; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (VI-d):Formula (VI-d) or a pharmaceutically acceptable salt thereof, wherein: X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O; X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that at least one of X1, X2, and X3is CHRLor C(RL)2; and further provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or wherein the compound is a compound of Formula (VI-e):Formula (VI-e) or a pharmaceutically acceptable salt thereof, wherein: X1is selected from the group consisting of S(O)0-2, CH2, CHRL, C(RL)2, and O;X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that 2-3 of X1, X2, and X3are independently CHRLor C(RL)2; one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; and each additional RLis independently selected from the group consisting of: C1-3 alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; and each R10is independently selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc.

49. The compound of claim 42, wherein the compound of Formula (VI) is selected from the group consisting of Compound Nos. 149, 149a, 149b, 149c, 173, 173a, 174, 174a, 186, 186a, 186b, 186c, 187a, 187a, 188, 188a, 189, 189a, 191, 191a, 191b, 191c, 191d, 192, 192a, 192b, 192c, 192d, 192e, 195, and 195a, as depicted in Table C1, or a pharmaceutically acceptable salt thereof.

50. The compound of any one of claims 24-37 or 42-49, wherein Y2is -CH2-; and R3is a 4-10 membered heterocyclyl having one ring nitrogen atom and 0-1 additional ring heteroatom selected from the group consisting of oxygen and nitrogen, wherein the heterocyclyl is optionally substituted with 1-6 Ra; optionally wherein52. A pharmaceutical composition comprising a compound as claimed in any one of claims 1-51, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

53. A method for treating a KRas-associated cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-51, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 52.

54. A method for treating a KRas-associated cancer in a subject in need thereof, the method comprising (a) determining that the cancer in the subject has a KRas dysregulation; and (b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-51, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 52.

55. A method of treating a KRas-associated cancer in a subject, the method comprising administering to a subject identified or diagnosed as having a cancer having a KRas dysregulation a therapeutically effective amount of a compound of any one of claims 1-51 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 52.

56. A method of treating a KRas-associated cancer in a subject, the method comprising: (a) determining that the cancer in the subject has a KRas dysregulation; and (b) administering to the subject a therapeutically effective amount of a compound of any one of claims 1-51 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 52.

57. The method of any one of claims 53-56, wherein the KRas-associated cancer is a mutant KRas-associated cancer.

58. The method of claim 57, wherein the mutant KRas-associated cancer is a KRasG12A-associated cancer, a KRas G12C-associated cancer, a KRas G12D-associated cancer, a KRas G12R-associated cancer, a KRas G12S-associated cancer, or a KRas G12V-associated cancer; or wherein the mutant KRas-associated cancer is a KRas G12D-associated cancer or a KRas G12V-associated cancer; or wherein the mutant KRas-associated cancer is a KRas G12D-associated cancer; or wherein the mutant KRas-associated cancer is a KRas G12R-associated cancer; or wherein the mutant KRas-associated cancer is a KRas G12V-associated cancer.

59. The method of any one of claims 54 or 56, wherein the step of determining that the cancer in the subject has a KRas dysregulation includes performing an assay to detect the KRas dysregulation (e.g., a KRas mutation) in a tumor sample from the subject.

60. The method of claim 59, wherein detecting the KRas dysregulation includes detecting a KRAS gene having a mutation corresponding to a substitution of glycine 12 in a KRas protein and / or a KRas protein having a substitution of glycine 12.

61. The method of claim 60, wherein the substitution of glycine 12 is a substitution to alanine, cysteine, aspartic acid, arginine, serine, or valine; or wherein the substitution of glycine 12 is a substitution to aspartic acid; or wherein the substitution of glycine 12 is a substitution to arginine; or wherein the substitution of glycine 12 is a substitution to valine.

62. The method of any one of claims 53-61, wherein the KRas-associated cancer is selected from the group consisting of: a hematological cancer, a soft tissue cancer, bile duct cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, mucinous carcinoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer, thymus cancer, thyroid cancer, urothelial cancer, uterine cancer, and a combination thereof; optionally wherein the KRas-associated cancer is pancreatic cancer; optionally wherein the KRas-associated cancer is selected from the group consisting of: a hematological cancer, brain cancer, cervical cancer, colon cancer, endometrial cancer,esophageal cancer, kidney cancer, liver cancer, lung cancer, mucinous carcinoma, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer, thymus cancer, urothelial cancer, and uterine cancer; optionally wherein the KRas-associated cancer is selected from the group consisting of: the cancer is a hematological cancer, bladder cancer, bile duct cancer, brain cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, kidney cancer, liver cancer, lung cancer, mucinous carcinoma, ovarian cancer, pancreatic cancer, rectal cancer, skin cancer, stomach cancer, testicular cancer (e.g., seminoma), thymus cancer, and uterine cancer; or optionally wherein the KRas-associated cancer is selected from the group consisting of: bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, esophageal or stomach cancer, leukemia, lung cancer (e.g., NSCLC), pancreatic cancer, and kidney cancer.

63. The method of any one of claims 53-62, comprising administering an additional therapy or therapeutic agent to the subject.

64. The method of claim 63, wherein the additional therapy or therapeutic agent is selected from the group consisting of Ras pathway targeted therapeutic agents, kinase-targeted therapeutics, mTORC1 inhibitors or degraders, YAP inhibitors or degraders, proteasome inhibitors or degraders, HSP90 inhibitors or degraders, farnesyl transferase inhibitors or degraders, PTEN inhibitors or degraders, signal transduction pathway inhibitors or degraders, checkpoint inhibitors, modulators of the apoptosis pathway, chemotherapeutics, angiogenesis- targeted therapies, immune-targeted agents, radiotherapy, and combinations thereof.

65. A compound of Formula (SII-a2), (SIV-a2), (SV-a2), (SVI-a2), or (SVII-a2):Formula (SVII-a2) or a salt thereof, wherein: ns is 0, 1, or 2; RSis C1-6alkyl optionally substituted with 1-3 substituents independently selected from the group consisting of Rcand Rb1; R11is selected from the group consisting of: NH2, NHPg, and N(Pg)2; R11aselected from the group consisting of: NHPg and N(Pg)2; each Pg is an independently selected nitrogen protecting group; R12is selected from the group consisting of: halo (e.g., -Br) and CN; b4 is 0 or 1; R10is selected from the group consisting of: -Cl, -F, -CN, and C1-3alkyl optionally substituted with 1-3 Rc; X1is selected from the group consisting of a bond, S(O)0-2, CH2, CHRL, C(RL)2, and O;X2and X3are independently selected from the group consisting of: CH2, CHRL, C(RL)2, O, and S(O)0-2, provided that no more than one of X1, X2, and X3is selected from the group consisting of: O and S(O)0-2; each RLis independently selected from the group consisting of C1-3alkoxy, -F, CN, and C1-3 alkyl optionally substituted with 1-3 Rc; or one pair of RLon the same or different ring carbon atom(s) taken together with the ring atom(s) connecting them form a C3-6cycloalkyl ring; R1is selected from the group consisting of: (i) a 4-10 membered heterocyclyl optionally substituted with 1-4 R7; (ii) an 8-12 membered bicyclic heterocyclyl, wherein the heterocyclyl comprises an endocyclic group selected from the group consisting of C(=O)NH and S(O)2NH, and wherein the heterocyclyl is further optionally substituted with 1-3 R7at one or more ring carbon atoms; and (iii), wherein b2 is 0, 1, 2, or 3; and A1and A2are independently selected from the group consisting of: N, CH, and CR7; each R7is independently selected from the group consisting of Raand Rb; Y2is a bond or a straight-chain C1-6alkylene optionally substituted with 1-6 RY; each RYis independently selected from the group consisting of: halo, cyano, -OH, oxo, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 alkyl, and C1-6 haloalkyl, or one pair of RYon the same or different carbon atom(s) taken together with the atom(s) connecting them forms a C3-6cycloalkyl ring or 4-6 membered heterocyclyl ring, each of which is optionally substituted with 1-3 independently selected C1-3 alkyl; R3is selected from the group consisting of: (a) 4-15 membered heterocyclyl optionally substituted with 1-6 substituents independently selected from the group consisting of: Raand Rb; and (b) -NRdRe; each Rais independently selected from the group consisting of:each Rbis independently selected from the group consisting of: -(Lb)b-Rb1and -Rb1, wherein: b is 1, 2, or 3; each -Lbis independently selected from the group consisting of: -O-, -N(H)-, -N(C1-3 alkyl)-, -S(O)0-2-, C(=O), and C1-3 alkylene; and each Rb1is independently selected from the group consisting of: C3-10cycloalkyl, 4-10 membered heterocyclyl, C6-10 aryl, and 5-10 membered heteroaryl, each of which is optionally substituted with 1-3 Rg; each Rcis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NRdRe, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)OH, C(=O)N(Rf)2, S(O)0-2(C1-6 alkyl), S(O)0-2(C1-6 haloalkyl), and S(O)1-2N(Rf)2; each Rdand Reis independently selected from the group consisting of: H, C(=O)C1-6 alkyl, C(=O)C1-6 haloalkyl, C(=O)OC1-6 alkyl, C(=O)OC1-6 haloalkyl, C(=O)N(Rf)2, S(O)1-2(C1-6alkyl), S(O)1-2(C1-6haloalkyl), S(O)1-2N(Rf)2, and C1-6alkyl optionally substituted with 1-3 Rh; each Rfis independently selected from the group consisting of: H and C1-6 alkyl optionally substituted with 1-3 Rh; each Rgis independently selected from the group consisting of: Rh, C1-3 alkyl, C1-3 haloalkyl, C3-5 cycloalkyl, and 4-5 membered heterocyclyl; and each Rhis independently selected from the group consisting of: halo, cyano, -OH, -C1-6 alkoxy, -C1-6 haloalkoxy, -NH2, -N(H)(C1-3 alkyl), and -N(C1-3 alkyl)2-.

66. Any of the compounds, compositions, combinations, pharmaceutical compositions, methods, uses, and processes as substantially provided herein.

Images